Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.111629 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society.
Eur J Endocrinol
November 2024
Department of Rheumatology, Amsterdam University Medical Center, Amsterdam 1081HV, The Netherlands.
Article Synopsis
- - The report by the European Calcified Tissue Society (ECTS) outlines evidence-based recommendations for preventing and treating glucocorticoid-induced osteoporosis (GIOP) in adults, aimed at healthcare providers who may not specialize in bone health.
- - Experts reviewed the literature and created 25 recommendations that categorize patients based on their fracture risk: medium, high, and very high, considering factors like age and history of fractures for appropriate treatment strategy.
- - Key general measures include optimizing calcium and vitamin D intake, assessing fracture risk regularly for those on glucocorticoids for three months or longer, and minimizing fall risks among patients.
Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report.
Osteoporos Int
November 2024
Weill Cornell Medicine, New York, NY, USA.
Osteoporosis is a metabolic bone disorder for which treatment options include antiresorptive therapies (e.g., bisphosphonates, denosumab); anabolics (e.
View Article and Find Full Text PDFIndications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS).
Front Pharmacol
August 2024
The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Shandong, Jinan, China.
Background: Teriparatide is approved for osteoporosis. Post-marketing surveillance is critical given its widespread use.
Objective: To investigate adverse events (AEs) associated with teriparatide using the FAERS database, compare association strengths for key AEs, and explore potential applications to provide clinical reference.
Gli1 Progenitors Mediate Glucocorticoid-Induced Osteoporosis In Vivo.
Int J Mol Sci
April 2024
State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
For a wide range of chronic autoimmune and inflammatory diseases in both adults and children, synthetic glucocorticoids (GCs) are one of the most effective treatments. However, besides other adverse effects, GCs inhibit bone mass at multiple levels, and at different ages, especially in puberty. Although extensive studies have investigated the mechanism of GC-induced osteoporosis, their target cell populations still be obscure.
View Article and Find Full Text PDFThe Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena.
Arch Osteoporos
April 2024
Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Background: In 2018, a grant was provided for an evidence-based guideline on osteoporosis and fracture prevention based on 10 clinically relevant questions.
Methods: A multidisciplinary working group was formed with delegates from Dutch scientific and professional societies, including representatives from the patient's organization and the Dutch Institute for Medical Knowledge. The purpose was to obtain a broad consensus among all participating societies to facilitate the implementation of the updated guideline.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!